1. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt

2. Location of Centers participating in the CIBMTR 2011 SUM-WW11_2.ppt.............................................................................................................................................................................................................................................................. Slide 2......................

3. Transplants SUM11_41.ppt Slide 3 Transplant Activity in the U.S. 1980-2010

4. SUM-WW11_3.ppt Allogeneic Stem Cell Sources by Recipient Age 2000-2009 Age 20 yrsAge 20 yrs Slide 4 Transplants, %

5. SUM-WW11_4.ppt Autologous Stem Cell Sources by Recipient Age 2000-2009 Age 20 yrsAge 20 yrs Slide 5 Transplants, %

6. SUM-WW11_5.ppt Trends in Transplants by Type and Recipient Age* 2000-2009 * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6 Transplants, % Allogeneic TransplantsAutologous Transplants

7. SUM11_5.ppt Trends in Transplants by Transplant Type and Recipient Age* 1989-2009 * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 Transplants, % Allogeneic TransplantsAutologous Transplants

8. Indications for Hematopoietic Stem Cell Transplants in the United States, 2009 SUM-WW11_8.ppt Slide 8 Number of Transplants

9. Indications for Hematopoietic Stem Cell Transplants for Age 20yrs in the United States, 2009 SUM-WW11_9.ppt Slide 9 Number of Transplants

10. SUM-WW11_10.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR 1992-2009 - by Donor Type and Graft Source - Slide 10 Number of Transplants * * Data incomplete

11. SUM-WW11_11.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR 1992-2009 - by Donor Type and Graft Source - Slide 11 Number of Transplants * * Data incomplete

12. SUM-WW11_12.ppt Unrelated Donor Stem Cell Sources by Recipient Age 2000-2009 Age 20 yrsAge 20 yrs Slide 12 Transplants, %

13. SUM-WW11_13.ppt Unrelated Cord Blood Transplants, by Age Registered with the CIBMTR 2000-2009 Slide 13 Number of Transplants * * Data incomplete

14. One-year survival after myeloablative conditioning for acute leukemias in any remission phase, CML or MDS, age 50 years, by year of transplant and graft source, 1988-2009 One-Year Survival, % SUM11_40.ppt Slide 14

15. SUM-WW11_14.ppt 100-day Mortality after Autologous Transplants, 2008-2009 Slide 15 Mortality, %

16. SUM-WW11_15.ppt 100-day Mortality after HLA-identical Sibling Transplants, 2008-2009 Slide 16 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, %

17. SUM-WW11_16.ppt 100-day Mortality after Unrelated Donor Transplants, 2008-2009 Slide 17 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, %

18. Causes of Death after Transplants performed in 2008-2009 Autologous Infection (8%) Other (16%) Organ Failure (2%) New Malignancy (1%) Primary Disease (73%) Unrelated Donor Infection (16%) Other (29%) Organ Failure (6%) Primary Disease (33%) New Malignancy (1%) GVHD (15%) SUM-WW11_17.ppt Slide 18 HLA-identical Sibling Infection (12%) Other (21%) Primary Disease (47%) GVHD (14%) Organ Failure (4%) New Malignancy (1%)

19. SUM-WW11_18.ppt Allogeneic Transplants, Registered with the CIBMTR, 2000-2009 - by Conditioning Regimen Intensity & Age - * * Data incomplete Slide 19 Number of Transplants

20. SUM-WW11_19.ppt Allogeneic Transplants after Reduced- intensity Conditioning, by Donor Type, Registered with CIBMTR 1998-2009 * * Data incomplete Slide 20 Number of Transplants

21. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for AML 2000-2009 - By Disease Status - Early (N=6,317) Intermediate (N=1,675) Advanced (N=2,645) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_20.ppt Slide 21

22. Years 026 13 45 Probability of Survival after Unrelated Donor Transplants for AML, 2000-2009 - By Disease Status - Early (N=4,260) Intermediate (N=2,864) Advanced (N=3,173) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_21.ppt Slide 22

23. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for AML, Age 20yrs, 2000-2009 - by Disease Status - Early (N=1,176) Intermediate (N=239) Advanced (N=250) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_22.ppt Slide 23

24. Years 026 13 45 Probability of Survival after Autologous Transplants for AML, 2000-2009 - by Disease Status - Early (N=1,979) Intermediate (N=672) Advanced (N=139) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_23.ppt Slide 24

25. Years 026 13 45 Probability of Survival after Allogeneic Transplants for MDS 2000-2009 - by Disease Status and Donor Type - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_24.ppt Slide 25 Early, sibling donor (N=667) Early, unrelated donor (N=752) Advanced, sibling donor (N=1,188) Advanced, unrelated donor (N=1,400)

26. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20yrs 2000-2009 - by Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_25.ppt Slide 26 Early (N=777) Intermediate (N=1,092) Advanced (N=196)

27. Years 026 13 45 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20yrs, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_26.ppt Slide 27 Intermediate (N=1,832) Advanced (N=278) Early (N=848)

28. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20yrs, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM11_27.ppt Slide 28 Intermediate (N=627) Advanced (N=568) Early (N=1,918)

29. Years 026 13 45 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20yrs, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_28.ppt Slide 29 Intermediate (N=928) Advanced (N=700) Early (N=1,458)

30. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2009 - By Disease Status and Transplant Year - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_29.ppt Slide 30 CP, 1998-2000 (N=2,291) AP, 1998-2000 (N=300) CP, 2001-2009 (N=2,524) AP, 2001-2009 (N=333)

31. Years 026 13 45 Probability of Survival after Autologous and HLA- matched Sibling Donor Hematopoietic Cell Transplantation for CLL, 2000-2009 by Donor Type and Conditioning Regimen Intensity 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_29.ppt Slide 31 Autologous transplant (N=253) Myeloablative conditioning(N=425) Reduced-intensity conditioning (N=752)

32. Years 026 13 45 Probability of Survival after Allogeneic Transplants for SAA, 2000-2009 - By Donor Type and Age - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_31.ppt Slide 32  20y, Sibling Donor (N=1,191)  20y, Sibling Donor (N=1,256)  20y, Unrelated Donor (N=574)  20y, Unrelated Donor (N=550)

33. Years 026 13 45 Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_32.ppt Slide 33 CR (N=2,419) Not in CR, sensitive (N=2,826) Not in CR, resistant (N=642)

34. Years 026 13 45 Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2009 - By Donor Type - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_33.ppt Slide 34 Sibling Donor (N=302) Unrelated Donor (N=183)

35. Years 026 13 45 Probability of Survival after Autologous Transplants for Follicular Lymphoma, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_34.ppt Slide 35 Sensitive (N=2,030) Resistant (N=172)

36. Years 026 13 45 Probability of Survival after HLA-identical Sibling Donor Transplants for Follicular Lymphoma, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_35.ppt Slide 36 Sensitive (N=698) Resistant (N=144)

37. Years 026 13 45 Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_36.ppt Slide 37 Sensitive (N=6,337) Resistant (N=453)

38. Years 026 13 45 Probability of Survival after Allogeneic Transplants for Diffuse Large B-Cell Lymphoma, 2000-2009 - By Disease Status - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_37.ppt Slide 38 Sensitive (N=383) Resistant (N=124)

39. Years 026 13 45 Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2009 - By Donor Type - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_38.ppt Slide 39 Sibling donor (N=498) Unrelated donor (N=325) Autologous (N=2,574)

40. Years 026 13 45 Probability of Survival after Transplants for Multiple Myeloma, 2000-2009 - By Donor Type - 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 SUM-WW11_39.ppt Slide 40 Sibling Donor (N=827) Unrelated donor (N=470) Autologous (N=23,197)